FAQ

CEP-32496

Known as: BRAF(V600E) Inhibitor CEP-32496 
An orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2014
02420122014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
[(11)C-carbonyl]CEP-32496: radiosynthesis, biodistribution and PET study of brain uptake in P-gp/BCRP knockout mice.
CEP-32496 is a novel, orally active serine/threonine-protein kinase B-raf (BRAF) (V600E) kinase inhibitor that is being… (More)
Is this relevant?
2012
2012
CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.
Mutations in the BRAF gene have been identified in approximately 7% of cancers, including 60% to 70% of melanomas, 29% to 83% of… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2012
2012
CEP-32496: A Novel Orally Active BRAF Inhibitor with Selective Cellular and In Vivo Antitumor Activity
Mutations in the BRAF gene have been identified in approximately 7% of cancers, including 60% to 70% of melanomas, 29% to 83% of… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2012
2012
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious…
The Ras/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway plays a central role in the regulation of cell… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 2
Is this relevant?
2012
2012
Preclinical Development CEP-32496: A Novel Orally Active BRAF Inhibitor with Selective Cellular and In Vivo Antitumor Activity
Mutations in the BRAF gene have been identified in approximately 7% of cancers, including 60% to 70% of melanomas, 29% to 83% of… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Review
2012
Review
2012
Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity
Mutations in the BRAF gene have been identified in approximately 7% of cancers, including 6070% of melanomas, 23-83% of papillary… (More)
Is this relevant?